ANI Pharmaceuticals (NASDAQ:ANIP) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, September 12th.
ANIP has been the subject of a number of other research reports. BidaskClub upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, June 13th. Zacks Investment Research downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 10th. Canaccord Genuity set a $75.00 target price on shares of ANI Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 16th. Finally, Cantor Fitzgerald began coverage on shares of ANI Pharmaceuticals in a research report on Monday, June 11th. They set a “buy” rating and a $85.00 target price on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. ANI Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $72.67.
Shares of ANIP traded down $0.97 during trading hours on Wednesday, hitting $54.99. The stock had a trading volume of 53,446 shares, compared to its average volume of 103,978. The company has a debt-to-equity ratio of 1.08, a current ratio of 3.84 and a quick ratio of 2.89. The company has a market cap of $668.70 million, a PE ratio of 15.23 and a beta of 2.62. ANI Pharmaceuticals has a 1-year low of $49.76 and a 1-year high of $74.70.
ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $1.13 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.34 by ($0.21). The firm had revenue of $47.27 million during the quarter, compared to analyst estimates of $50.70 million. ANI Pharmaceuticals had a net margin of 0.06% and a return on equity of 27.76%. Analysts expect that ANI Pharmaceuticals will post 4.49 EPS for the current fiscal year.
Several large investors have recently bought and sold shares of ANIP. Mount Yale Investment Advisors LLC bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter worth approximately $102,000. Sei Investments Co. raised its holdings in shares of ANI Pharmaceuticals by 56.9% in the 1st quarter. Sei Investments Co. now owns 2,252 shares of the specialty pharmaceutical company’s stock worth $131,000 after purchasing an additional 817 shares during the period. Piedmont Investment Advisors LLC bought a new stake in shares of ANI Pharmaceuticals in the 2nd quarter worth approximately $140,000. Trexquant Investment LP purchased a new position in ANI Pharmaceuticals in the 1st quarter valued at approximately $205,000. Finally, Millennium Management LLC purchased a new position in ANI Pharmaceuticals in the 4th quarter valued at approximately $210,000. 60.67% of the stock is currently owned by institutional investors.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.
Recommended Story: How to Invest in the Dividend Aristocrat Index
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.